Log in to your Inderes Free account to see all free content on this page.
Ultimovacs
Be the first to follow this company
Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
Oslo Børs
ULTI
Daily low / high price
-
Market cap
-
Turnover
-
Volume
-
Financial calendar
Interim report
06.11.2024
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Gjelsten Holding AS | 18.9 % | 18.9 % |
Radforsk Investeringsstiftelse | 4.4 % | 4.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio